Xtandi drug combo reduces risk of prostate cancer metastasis and death.

Pfizer and Astellas have reported that their drug Xtandi, in combination with leuprolide, reduces the risk of metastasis and death in prostate cancer by 58%. The Phase III EMBARK trial tested Xtandi plus leuprolide and Xtandi as a monotherapy against placebo plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. The companies believe that the data shows the potential for Xtandi to be added to the standard of care if a label expansion is approved.